Insider Transactions in Q3 2023 at Phreesia, Inc. (PHR)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
125
-0.3%
|
$2,375
$19.79 P/Share
|
|
Sep 18
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
130
-0.55%
|
$2,470
$19.7 P/Share
|
|
Sep 14
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-1.66%
|
$40,000
$20.16 P/Share
|
|
Sep 14
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,210
-1.86%
|
$44,200
$20.17 P/Share
|
|
Sep 14
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
2,953
-3.06%
|
$59,060
$20.16 P/Share
|
|
Sep 13
2023
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,907
-0.26%
|
$78,140
$20.75 P/Share
|
|
Sep 13
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
934
-1.11%
|
$18,680
$20.75 P/Share
|
|
Sep 13
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,826
-0.74%
|
$36,520
$20.75 P/Share
|
|
Sep 13
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,256
-1.34%
|
$65,120
$20.75 P/Share
|
|
Sep 13
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
119
-0.74%
|
$2,380
$20.75 P/Share
|
|
Sep 13
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,059
-0.47%
|
$41,180
$20.75 P/Share
|
|
Sep 13
2023
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,555
-0.26%
|
$131,100
$20.75 P/Share
|
|
Sep 13
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
3,606
-1.8%
|
$72,120
$20.75 P/Share
|
|
Sep 13
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,957
-2.19%
|
$79,140
$20.75 P/Share
|
|
Sep 12
2023
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,559
+0.87%
|
-
|
|
Sep 12
2023
|
Janet Gunzburg Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,404
+5.41%
|
-
|
|
Sep 12
2023
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,826
+3.03%
|
-
|
|
Sep 12
2023
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,466
+4.3%
|
-
|
|
Sep 12
2023
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Indirect |
273
+3.27%
|
-
|
|
Sep 12
2023
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
11,853
+1.78%
|
$59,265
$5.82 P/Share
|
|
Sep 12
2023
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
3,279
+1.56%
|
-
|
|
Sep 12
2023
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,260
+0.89%
|
-
|
|
Sep 12
2023
|
Michael J. Davidoff SVP, Payer Business |
BUY
Grant, award, or other acquisition
|
Direct |
6,559
+6.15%
|
-
|
|
Sep 12
2023
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,406
+6.61%
|
-
|
|
Sep 08
2023
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.87%
|
$60,000
$2.03 P/Share
|
|
Aug 24
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
11,042
-8.67%
|
$287,092
$26.39 P/Share
|
|
Jul 31
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
272
-0.68%
|
$8,432
$31.72 P/Share
|
|
Jul 31
2023
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+0.7%
|
$9,765
$31.72 P/Share
|
|
Jul 31
2023
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+1.04%
|
$9,765
$31.72 P/Share
|
|
Jul 31
2023
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+1.21%
|
$9,765
$31.72 P/Share
|
|
Jul 21
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
1,075
-1.14%
|
$33,325
$31.75 P/Share
|
|
Jul 14
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
624
-0.52%
|
$20,592
$33.72 P/Share
|
|
Jul 14
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
1,122
-1.17%
|
$37,026
$33.72 P/Share
|
|
Jul 14
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-0.95%
|
$26,631
$33.72 P/Share
|
|
Jul 14
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,172
-0.91%
|
$38,676
$33.72 P/Share
|
|
Jul 14
2023
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,089
-0.25%
|
$101,937
$33.72 P/Share
|
|
Jul 14
2023
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
1,948
-0.95%
|
$64,284
$33.72 P/Share
|
|
Jul 14
2023
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,781
-0.25%
|
$58,773
$33.72 P/Share
|
|
Jul 13
2023
|
Lisa Egbuonu Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,049
+41.43%
|
-
|
|
Jul 08
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
861
-1.0%
|
$24,108
$28.87 P/Share
|